,,ii #aahth ,,congress #ast ,session ,s4 #bcje ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,july #ac1 #bjbc,mr4 ,lee 7for himself1 ,mr4 ,lujn1 ,mr4 ,braun1 and ,mr4 ,vance7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,a ,,bill ,to improve the requirements for making a determination of interchangeability of a biological product and its reference product4 #a4 ,short title ,this ,act may be cited as the ,biosimilar ,red ,tape ,elimination ,act4 #b4 ,biosimilar biological products 7a7 ,in general ,section #cea7k7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7k77 is amended-- 7#a7 in the subsection heading1 by striking or interchangeable2 7#b7 in paragraph 7#b7-- 7,a7 by striking subparagraph 7,b72 7,b7 by redesignating clauses 7ii7 and 7iii7 of subparagraph 7,a7 as subparagraphs 7,b7 and 7,c71 respectively1 and adjusting the margins accordingly2 7,c7 in subparagraph 7,a7-- 7i7 in clause 7i71 by redesignating subclauses 7,i7 through 7,v7 as clauses 7i7 through 7v71 respectively1 and adjusting the margins accordingly2 7ii7 in clause 7i71 as so redesignated by clause 7i7 of this subparagraph1 by redesignating items 7aa7 through 7cc7 as subclauses 7,i7 through 7,,iii71 respectively1 and adjusting the margins accordingly2 and 7iii7 by striking 7,a7 ,in ,general and all that follows through ,an application submitted under this subsection shall include information and inserting the following3 7,a7 ,in general ,an application submitted under this subsection shall include information 2 7,d7 in subparagraph 7,b71 as so redesignated by subparagraph 7,c7 of this paragraph1 by striking clause 7i77,i7 and inserting subparagraph 7,a77i72 and 7,e7 in subparagraph 7,c71 as so redesignated by subparagraph 7,c7 of this paragraph1 by redesignating subclauses 7,i7 through 7,,iii7 as clauses 7i7 through 7iii71 respectively1 and by adjusting the margins accordingly2 7#c7 by amending paragraph 7#d7 to read as follows3 7#d7 ,interchangeability 7,a7 ,in general ,a biological product licensed under this subsection shall be deemed to be interchangeable with the reference product4 7,b7 ,congressional briefing prior to certain study requirements ,the ,secretary may require the sponsor of an application submitted under this section to conduct a study to evaluate the risk1 in terms of safety1 purity1 or potency1 of alternating or switching between the use of the biological product that is the subject of the application and the reference product1 if1 before requiring such a study1 the ,secretary first holds a private briefing with the chair and ranking member of the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the chair and the ranking member of the ,committee on ,energy and ,commerce of the ,house of ,representatives1 to explain why such a study is necessary for the biological product1 what information the ,secretary expects such a study to reveal1 what alternatives to such study have been considered1 and why those alternatives are not sufficient4 2 7#d7 by striking paragraph 7#f72 and 7#e7 in paragraph 7#h77;,d7-- 7,a7 in clause 7i71 by striking class2 and and inserting class42 7,b7 by striking clause 7ii72 and 7,c7 by striking description of-- and all that follows through criteria that the ,secretary and inserting description of the criteria that the ,secretary4 7b7 ,conforming amendments 7#a7 ,section #cea7;i77#c7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7;i77#c77 is amended by striking that is shown to meet the standards described in subsection 7k77#d7 and inserting licensed under subsection 7k74 7#b7 ,section #ceb;,a of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfc-a7 is amended by striking and interchangeable biosimilar biological products each place it appears4 7#c7 ,section #gdd;,g7#ad7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;j-#ea7ad77 is amended by striking 1 including a supplement requesting that the ,secretary determine that the biosimilar biological product meets the standards for interchangeability described in section #cea7k77#d7 of the ,public ,health ,service ,act4 7#d7 ,by amending subsection 7l7 of section #eje;,b of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee;c7 to read as follows3 7l7 ,biosimilar biological products ,a biological product for which an application is submitted under section #cea7k7 of the ,public ,health ,service ,act shall be considered to have a new active ingredient for purposes of this section1 except that a pediatric assessment shall not be required for a claimed indication in a relevant pediatric population if the assessment would involve-- 7#a7 a condition of use that has not been previously approved for the reference product2 or 7#b7 a dosage form1 strength1 or route of administration that differs from that of the reference product4 4 7c7 ,application ,the amendments made by subsection 7a77#d7 to section #cea7k77#f7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7k77#f77 shall apply only with respect to applications approved under section #cea7k7 of such ,act on or after the date of enactment of this ,act4 ,any period of exclusivity granted under section #cea7k77#f7 of such ,act with respect to an application approved under such section #cea7k7 before the date of enactment of this ,act shall apply in accordance with such section #cea7k77#f71 as in effect on the day before the date of enactment of this ,act4